文献速递头颈外科

肿瘤治疗电场作为头颈癌多模式治疗的新型联合伙伴

Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer.
PubMed 文献 · Head Neck · 2023-03-05

本研究在两种人头颈鳞癌细胞系中评估肿瘤治疗电场(TTFields)联合放疗和化疗的效果,发现放疗联合TTFields降低克隆存活的程度与放疗联合同步顺铂相当,三者联合进一步降低克隆存活,并增加细胞凋亡和DNA双链断裂,提示TTFields可能是局部晚期头颈鳞癌多模式治疗的有前景的联合伙伴。

要点

  • 放疗联合TTFields降低克隆存活的程度与放疗联合同步顺铂相当。
  • 放疗联合同步顺铂再加TTFields进一步降低克隆存活。
  • TTFields联合放疗或放疗联合同步顺铂增加细胞凋亡和DNA双链断裂。

核心结论

  • TTFields治疗似乎是局部晚期头颈鳞癌多模式治疗中有前景的联合伙伴。
  • TTFields可用于强化放化疗或作为化疗的替代方案。

研究设计与样本

  • 研究使用两种人头颈鳞癌细胞系(Cal27、FaDu),接受五种不同处理:TTFields、放疗加或不加TTFields、放疗联合同步顺铂加或不加TTFields。
  • 采用克隆形成实验以及DAPI、caspase-3激活和γH2AX foci的流式细胞分析量化效果。

主要发现

  • 放疗联合TTFields降低克隆存活的程度与放疗联合同步顺铂相当。
  • 放疗联合同步顺铂再加TTFields进一步降低克隆存活。
  • TTFields联合放疗或放疗联合同步顺铂增加细胞凋亡和DNA双链断裂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We aimed to demonstrate the effects of tumor treating fields (TTFields) in head and neck squamous cell carcinoma (HNSCC) cells when combined with radiotherapy (RT) and chemotherapy. METHODS: Two human HNSCC cell lines (Cal27, FaDu) received five different treatments: TTFields, RT +/- TTFields and RT + simultaneous cisplatin +/- TTFields. Effects were quantified using clonogenic assays and flow cytometric analyses of DAPI, caspase-3 activation and γH2AX foci. RESULTS: Treatment with RT + TTFields decreased the clonogenic survival as strong as treatment with RT + simultaneous cisplatin. The triple combination of RT + simultaneous cisplatin + TTFields even further decreased the clonogenic survival. Accordingly, combination of TTFields with RT or RT + simultaneous cisplatin increased cellular apoptosis and DNA double-strand breaks. CONCLUSION: TTFields therapy seems a promising combination partner in the multimodal treatment of locally advanced HNSCC. It could be used to intensify chemoradiotherapy or as alternative to chemotherapy.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Regnery S, Franke H, Held T, et al. Tumor treating fields as novel combination partner in the multimodal treatment of head and neck cancer. Head Neck. 2023. PMID: 36872620. doi:10.1002/hed.27298

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。